35th week of 2013 patent applcation highlights part 60 |
Patent application number | Title | Published |
20130225488 | Antidiabetic Comppounds - The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity. | 2013-08-29 |
20130225489 | METHODS FOR ADMINISTERING HYPOGLYCEMIC AGENTS - The present invention relates to methods of administering hypoglycemic agents and/or GLP-1 agonists. | 2013-08-29 |
20130225490 | Antibodies That Inhibit TSLP Activity - The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. | 2013-08-29 |
20130225491 | Methods and Kits for Treating Disease By Administering Insulin-Like Growth Factor Binding Protein-2 - The present invention is directed to methods of treating Type 1-diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods treating Type 2 diabetes by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is further directed to methods treating insulin resistance by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is directed to methods of treating hepatic steatosis by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods lowering blood glucose and serum insulin in non-diabetic subjects by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. | 2013-08-29 |
20130225492 | Sustained-Release Pharmaceutical Composition - Provided is a pharmaceutical composition, including a drug and a collagen, in which the composition is satisfactory in handleability and has sustained-release property. The sustained-release pharmaceutical composition includes: a drug; a collagen; and at least one kind of sugar selected from monosaccharides, disaccharides, trisaccharides, and tetrasaccharides. The inventors of the present invention have found that the in vivo administration of a collagen solution containing a sugar results in the gelation of a collagen. Based on this finding, the inventors have found that a composition containing a drug, a collagen, and a sugar can control the release rate of the drug, and such composition can be used as a sustained-release pharmaceutical composition. | 2013-08-29 |
20130225493 | FGF-18 Truncated Variants Having Increased Receptor Specificity And Uses Thereof - The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders. | 2013-08-29 |
20130225494 | FORMULATIONS HAVING AN ALPHA V BETA 3 ANTAGONIST AND AN ALPHA 2 BETA 1 ANTAGONIST FOR ANTI-ANGIONIC THERAPY - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an αVβ1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12). | 2013-08-29 |
20130225495 | FORMULATIONS HAVING AN ANTAGONIST OF ALPHA 5 BETA 1 FOR ANTI-ANGIOGENESIS AND CANCER TREATMENT - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12). | 2013-08-29 |
20130225496 | Albumin Variants - The invention relates to variants of albumin. The invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of preparing the variants and to methods of using the variants. | 2013-08-29 |
20130225497 | SKIN COLLAGEN PRODUCTION-PROMOTING AGENT - A skin collagen production-promoting agent includes a milk protein fraction having following properties (a) to (c) as an active ingredient: (a) being derived from milk, (b) containing proteins having a molecular weight determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 6000 to 150,000 daltons, and (c) containing 12 to 14 wt % of basic amino acids with respect to the constituent amino acid composition, and having a basic amino acid/acidic amino acid ratio of 0.5 to 0.7. | 2013-08-29 |
20130225498 | COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES CONTAINING CCL5 - There is provided a composition for preventing or treating neurodegenerative diseases, including one or two or more selected from the group consisting of a chemoattractant CCL5, a CCL5 expression regulator, and a CCL5 activator as an active ingredient, in which by confirming through a morris water maze task that the CCL5 recovers memory loss and improves spatial cognition ability, it has been found that the composition including any one or two or more selected from the group consisting of the CCL5, the CCL5 expression regulator, and the CCL5 activator can be usefully employed as a pharmaceutical composition or a food composition for preventing or treating neurodegenerative diseases. | 2013-08-29 |
20130225499 | METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE - The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil. | 2013-08-29 |
20130225500 | ANALGESIC ACTIVE PEPTIDE VGG, PREPARATION AND USE THEREOF - The present invention provides an active peptide purified from scorpions, and derivatives, analogues and active fragment which are produced by using genetic engineering technology. The analgesic active peptide VGG is extracted, separated and purified from scorpion, and its amino acid sequence is shown as below: | 2013-08-29 |
20130225501 | SKIN COLLAGEN PRODUCTION-PROMOTING AGENT - Skin quality is improved by orally administering a cystatin and/or a degraded product of cystatin in an amount of 10 μg/day or more per adult, or applying a composition that includes a cystatin and/or a degraded product of cystatin in an amount of 0.001 to 2 wt % based on a total amount of the composition. | 2013-08-29 |
20130225502 | COMBINATION THERAPY WITH W T 1 PEPTIDE VACCINE AND TEMOZOLOMIDE - The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide. | 2013-08-29 |
20130225503 | TEX14 PEPTIDES AS NOVEL ANTITUMOR AGENTS - Embodiments of the present invention regard TEX14 peptides for cancer treatment. In particular, the TEX14 peptides comprise a GPPX3Y motif. Methods, compositions, and kits are encompassed. | 2013-08-29 |
20130225504 | USE OF A CORN PEPTIDIC HYDROLYZATE AS AN ACTIVE AGENT STIIMULATING HAIR GROWTH - The invention relates to a cosmetic treatment method intended to stimulate hair growth, restore hair growth, and/or limit hair loss. The cosmetic treatment method includes providing a composition comprising at least one corn ( | 2013-08-29 |
20130225505 | MUTEINS OF HUMAN TEAR LIPCALIN FOR TREATING NEOVASCULAR DISEASE OF THE ANTERIOR SEGMENT OF THE HUMAN EYE - Disclosed herein is a method of treating neovascular diseases of the anterior segment of the human eye, the method comprising administering to the eye muteins of human tear lipocalin that target VEGF. | 2013-08-29 |
20130225506 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY - Novel template-fixed β-hairpin peptidomimetics of the general formula (I), wherein the single elements T or P are α-amino acid residues connected from the carbonyl (C═O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these β-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells. | 2013-08-29 |
20130225507 | METHOD OF PRODUCING FR901228 - Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. | 2013-08-29 |
20130225508 | PEPTIDE CAPABLE OF BINDING TO IMMUNOGLOBULIN - The present invention relates to a peptide capable of binding to an immunoglobulin, and to a fusion protein containing such a peptide. The present invention also relates to a pharmaceutical composition for the treatment or prevention of a disease caused by binding between C1q and an immunoglobulin, which comprises a peptide capable of binding to the immunoglobulin or a fusion protein with such a peptide, and to the like. The pharmaceutical composition provided by the present invention is effective particularly in treating arthritis and rheumatism. | 2013-08-29 |
20130225509 | METHOD TO ENHANCE ENDURANCE - The present invention relates to a method of enhancing endurance of a human subject through administration of alanyl-glutamine or alanyl-glutamine salt. | 2013-08-29 |
20130225510 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS - The invention provides an orally-administrable nutritional product comprising a dipeptide including a branched chain amino acids (BCAA). In one embodiment, the nutritional product comprises a dipeptide selected from at least one of the following: alanyl-leucine, alanyl-isoleucine, alanyl-valine, glycyl-leucine, glycyl-isoleucine, and glycyl-valine. | 2013-08-29 |
20130225511 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES - The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions. | 2013-08-29 |
20130225512 | DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION - Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed. | 2013-08-29 |
20130225513 | METHODS AND FORMULATIONS FOR TREATING SIALIC ACID DEFICIENCIES - The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations. | 2013-08-29 |
20130225514 | C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF - The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R | 2013-08-29 |
20130225515 | METHOD FOR ISOLATING SMALL MOLECULES WITH IMPORTANT BIOLOGICAL ACTIVITY USING YEAST - Methods of isolating biologically active molecules from an organism, for example from a fungus, are described. The methods involve isolating an active molecule which possesses a specific biological activity on, in or against wild-type yeast cells, but not on, in or against yeast cells that express a given ABC transporter from a given organism, including but not limited to | 2013-08-29 |
20130225516 | TOPICAL COMPOSITIONS COMPRISING FIPRONIL AND PERMETHRIN AND METHODS OF USE - The subject matter disclosed herein is directed to stable, highly-effective topical formulations comprising permethrin, fipronil and a solvent system that is sufficient to solubilize these two active ingredients and limit degradation of fipronil to its sulfone, and their uses in topical applications on animals and the environment. Useful formulations comprise from about 30% to about 55% (w/w) permethrin and about 2 to 15% (w/w) fipronil and a solvent system that comprises N-methylpyrrolidone and a glycol, glycol ether, glycol ester, fatty acid ester or neutral oil, wherein the N-methylpyrrolidone and glycol, glycol ether, glycol ester, fatty acid ester or neutral oil are present in a weight:weight ratio of from about 1:2.0 to about 1:3.5, glycol, glycol ether, glycol ester, fatty acid ester or neutral oil to n-methylpyrrolidone. These two actives when combined in the described amounts have been found to have unexpected enhanced repellent activity against stable fly. However, it is the formulations described herein that provide solvency and stability that maintain synergistic concentrations after application on an animal. | 2013-08-29 |
20130225517 | Therapeutic Compounds - The invention provides compounds of formula I: | 2013-08-29 |
20130225518 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY - Provided herein are methods for treating or preventing advanced non-small cell lung cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of erlotinib or a cytidine analog to a patient having advanced non-small cell lung cancer. | 2013-08-29 |
20130225519 | NUCLEOSIDE PHOSPHORAMIDATES - A nucleoside compound having activity against hepatitis C virus is disclosed. | 2013-08-29 |
20130225520 | Uracyl Spirooxetane Nucleoside Phosphoramidates - This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate which inhibits the hepatitis C virus (HCV). | 2013-08-29 |
20130225521 | PREVENTION OF MICRONUTRIENT DEFICIENCIES ASSOCIATED WITH COMMON DISABILITIES IN THE OVER 50 ADULT - A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B | 2013-08-29 |
20130225522 | COMPOSITION FOR RELIEVING STIMULUS OF SKIN CAUSED BY DYE - The present invention relates to a composition containing a carbohydrate or a derivative thereof as an active ingredient. The composition relieves stimulus of the skin caused by dye and prevents inflammation caused by dye. In addition, the present invention relates to a hair dye composition comprising a composition containing a carbohydrate or a derivative thereof as an active ingredient. The hair dye composition reduces stimulus of the skin and inflammation caused by dye. | 2013-08-29 |
20130225523 | GLYCODENDRIMERS OF POLYPROPYLETHERIMINE - A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting 16 terminal carboxylic acid groups, and b) conjugated to said core 2, 3, 4 or 5 glucosamine molecules, wherein each glucosamine is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions. | 2013-08-29 |
20130225524 | Chemical Compounds - The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: | 2013-08-29 |
20130225525 | Combined Treatment Utilizing VB-201 - Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed. | 2013-08-29 |
20130225526 | MEDICINE, FOOD AND DRINK OR FEED CONTAINING SPHINGOMYELIN - It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk. | 2013-08-29 |
20130225527 | Phosphorus Derivatives as Kinase Inhibitors - The invention features compounds of the general formula: | 2013-08-29 |
20130225528 | Phosphorus Derivatives as Kinase Inhibitors - The invention features compounds of the general formula: | 2013-08-29 |
20130225529 | PHOSPHO-ESTER DERIVATIVES AND USES THEREOF - Phospho-ester compounds and pharmaceutical compositions thereof administered by the respiratory and other routes for the prevention and/or treatment of lung and brain cancer and precancerous conditions thereof, for the treatment of pain, for the treatment of skin disorders, for treating and/or preventing inflammation-related diseases, and for the treatment and prevention of cancer. | 2013-08-29 |
20130225530 | WOGONIN FOR THE PREVENTION AND THERAPY OF CARDIAC HYPERTROPHY - The present invention relates to a pharmaceutical composition for use as a medicament for the treatment or prophylaxis of cardiac hypertrophy, comprising at least one compound of formula (I), wherein: R | 2013-08-29 |
20130225531 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN - A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans. | 2013-08-29 |
20130225532 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES - Methods and compositions for detection of drug resistant pathogens and treatment against infections thereof are provided. Methods for detection of oseltamivir-resistant influenza viruses by competitive binding assays utilizing non-oseltamivir influenza virus neuraminidase inhibitors and oseltamivir carboxylate are provided. Influenza virus neuraminidase inhibitors coupled to sensors and useful for employment in the methods of the invention are disclosed. Novel phosphonate compounds active as neuraminidase inhibitors against wild-type and oseltamivir-resistant influenza strains of H1N1, H5N1 and H3N2 viruses are disclosed. An enantioselective synthetic route to preparation of these phosphonate compounds via sialic acid is provided. | 2013-08-29 |
20130225533 | DOCOSAHEXAENOIC ACID BOUND IN PHOSPHOLIPIDS AND METHOD OF RECOVERING SAME FROM A NATURAL SOURCE - Medicaments and therapeutic compositions contain (1) phospholipids having 4,7,10,13,16,19-docosahexaenoic acid covalently bound thereto and (2) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, wherein about 25% of the total 4,7,10,13,16,19-docosahexaenoic acid moieties in the composition are covalently bound to phospholipids, and wherein components (1) and (2) are present in amounts effective to support overall neurological health in a subject. | 2013-08-29 |
20130225534 | METHODS FOR TREATING AN INORGANIC SLURRY - A method for treating an inorganic slurry to preserve the slurry against bacterial contamination, including (I) providing a slurry in a substantially homogeneous phase, and then (II) adding to the slurry an effective amount of a composition containing: (a) a tetrakis (hydroxyorgano) phosphonium salt selected from the group consisting of tetrakis (hydroxymethyl) phosphonium sulphate, tetrakis (hydroxymethyl) phosphonium chloride, tetrakis (hydroxymethyl) phosphonium phosphate, tetrakis (hydroxymethyl) phosphonium nitrate and tetrakis (hydroxymethyl) phosphonium oxalate; and (b) a dispersant selected from the group consisting of (i) a phosphonated compound containing at least one tertiary nitrogen atom and (ii) a homopolymer of an unsaturated acid; and (III) preserving the slurry against bacterial contamination, whilst avoiding instantaneous heterogeneous thickening of the slurry due to the tetrakis (hydroxyorgano) phosphonium salt. | 2013-08-29 |
20130225535 | SYNERGISTIC FUNGICIDAL COMPOSITION - The present invention relates to a composition comprising a combination of a morpholine fungicide; a phthalimide fungicide; and a phosphorus containing fungicide, wherein the composition has a synergistically enhanced activity. | 2013-08-29 |
20130225536 | Methods for Accelerated Return of Skin Integrity and for the Treatment of Impetigo - Methods of treatment and dosage regimes using hydrophobic gel or foam compositions comprising a tetracycline antibiotic for accelerating the return of skin integrity and or in treating or alleviating a disorder including impetigo, acne, rosacea, a skin disease caused by a bacteria or a tetracycline antibiotic responsive disease, wherein the foam composition or gel is administered topically to a target area on a subject having the disorder and wherein the target area comprises an area of skin, or mucosa or an eye. | 2013-08-29 |
20130225537 | METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT - The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions. | 2013-08-29 |
20130225538 | BIOABSORBABLE POLYMER COMPOSITIONS EXHIBITING ENHANCED CRYSTALLIZATION AND HYDROLYSIS RATES - A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend. | 2013-08-29 |
20130225539 | METHOD FOR PRODUCING CRYSTALLINE 5-AMINOSALICYLIC ACID - The invention relates to a method for producing crystalline 5-aminosalicylic acid with a particularly high tap and/or bulk density. | 2013-08-29 |
20130225540 | SUPPRESSION OF GLIAL FIBRILLARY ACIDIC PROTEIN - Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell. Also provided are compounds useful for the treatment of Alexander disease in subjects at risk of or diagnosed with Alexander disease and methods for the identification of such compounds. | 2013-08-29 |
20130225541 | Elevated PSMA Identifies Lethal Prostate Cancers - Prostate cancer (PC) is an entity that encompasses different types of tumors, including adenocarcinomas and non-adenocarcinomas. Adenocarcinomas and non-adenocarcinomas respond to, and therefore should be treated, with different treatments. Even within the adenocarcinomas, the lethality of tumors is highly variable, from low risk/indolent/non-life threatening to high risk/lethal. The inability to accurately predict the behavior of a particular cancer makes treatment decisions difficult and highly inexact. Elevated expression of prostate specific membrane antigen (PSMA) expression is a molecular hallmark of lethal prostate adenocarcinoma. Assessment of PSMA expression levels to predict the behavior of a particular cancer will be useful in the diagnosis and treatment of PC. | 2013-08-29 |
20130225542 | Therapeutic Gestagens For The Treatment Of Premenstrual Dysphoric Disorder - This invention describes the use of a therapeutic gestagen (e.g., drospirenone, cyproterone acetate, dienogest) for the production of a pharmaceutical agent for the treatment of premenstrual dysphoric disorder (PMDD), optionally in combination with a natural or synthetic estrogen (e.g., estradiol or ethinylestradiol). | 2013-08-29 |
20130225543 | SPECIFIC REGULATION OF CYTOKINE LEVELS BY HDAC6 INHIBITORS - The invention provides for methods of treating a disease using HDAC6 inhibitors that modulate the extracellular level of a subset of cytokines. The invention also provides for compositions for treating a disease associated with a modulation in the extracellular level of a subset of cytokines. | 2013-08-29 |
20130225544 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 2013-08-29 |
20130225545 | PORPHYRIN TREATMENT OF NEURODEGENERATIVE DISEASES - Compositions and methods of treating a neurodegenerative disorder are disclosed herein. | 2013-08-29 |
20130225546 | NOVEL SYNTHETIC PROCEDURE AND CANCER TREATMENT WITH CISPLATIN DERIVATIVES - A method of reducing the in vivo viability of cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells has steps of:
| 2013-08-29 |
20130225547 | PROTEASOME INHIBITORS AND USES THEREOF - A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors. | 2013-08-29 |
20130225548 | Pyridine Derivative and Medicinal Agent - A main object of the present invention is to provide a novel pyridine derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. | 2013-08-29 |
20130225549 | DIHYDROPTERIDINONES I - The present invention relates to dihydropteridinones, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Aβ peptides. | 2013-08-29 |
20130225550 | SALTS - This invention relates to a hydrochloride, malate, oxalate and tartrate salt forms of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of each of these salts, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment. | 2013-08-29 |
20130225551 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER - The present invention provides compounds of formula I | 2013-08-29 |
20130225552 | HETEROBICYCLIC COMPOUNDS - Heterobicyclic compounds of Formula (I): | 2013-08-29 |
20130225553 | PYRAZOLOQUINOLINE COMPOUND - The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, bladder/urethral diseases, and the like, and thus, have found that a pyrazoloquinoline compound has a PDE9-inhibiting action, thereby completing the present invention. | 2013-08-29 |
20130225554 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS - A compound of formula (I): | 2013-08-29 |
20130225555 | Imidazoquinolines with Immuno-Modulating Properties - The present invention provides compounds of formula (I) | 2013-08-29 |
20130225556 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS - The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer. | 2013-08-29 |
20130225557 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE - Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2013-08-29 |
20130225558 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE - This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-08-29 |
20130225559 | S-MIRTAZAPINE FOR THE TREATMENT OF HOT FLUSH - The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush. | 2013-08-29 |
20130225560 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors - A method for improving cognition comprising administering to a patient certain alpha-7 receptor agonists and an acetylcholinesterase inhibitor is described together with related compositions. | 2013-08-29 |
20130225561 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure. | 2013-08-29 |
20130225562 | PYRIDYLTRIAZOLES - The present invention encompasses compounds of general formula (1) wherein the groups R | 2013-08-29 |
20130225563 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR - The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases. | 2013-08-29 |
20130225564 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH - Provided herein are Aminopurine Compounds having the following structure: | 2013-08-29 |
20130225565 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are 2,5-disubstituted arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition. | 2013-08-29 |
20130225566 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim | 2013-08-29 |
20130225567 | 5-Alkynyl Pyridine - 5-alkynyl-pyridine of general formula (I) | 2013-08-29 |
20130225568 | TRIAZOLOPYRAZINE DERIVATIVES - Compounds of the formula I | 2013-08-29 |
20130225569 | FUROPYRIDINE DERIVATIVES - Compounds of the formula I | 2013-08-29 |
20130225570 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES - Methods for treating respiratory and gastrointestinal diseases mediated by a P2X | 2013-08-29 |
20130225571 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES - The invention relates to new crystalline forms of processes for manufacturing a compound of formula 5, | 2013-08-29 |
20130225572 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor - The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) | 2013-08-29 |
20130225573 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE - A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor. | 2013-08-29 |
20130225574 | OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF - The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K. | 2013-08-29 |
20130225575 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS - Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from certain neurological conditions. | 2013-08-29 |
20130225576 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 2013-08-29 |
20130225577 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS - The instant invention provides compounds of formula I which are Jak inhibitors, and as such are useful for the treatment of Jak-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer. | 2013-08-29 |
20130225578 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF - Provided herein are 7-cyclylquinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2013-08-29 |
20130225579 | CYANOQUINOLINE DERIVATIVES - Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, | 2013-08-29 |
20130225580 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists. | 2013-08-29 |
20130225581 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE - The present invention provides a nitrogen-containing aromatic heterocyclic derivative represented by formula (I): | 2013-08-29 |
20130225582 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 2013-08-29 |
20130225583 | SUBSTITUTED AMINO-TRIAZOLYL PDE10 INHIBITORS - The present invention is directed to substituted amino-triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. | 2013-08-29 |
20130225584 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS - The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, for example Parkinson's disease or Alzheimer's disease. | 2013-08-29 |
20130225585 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF - Disclosed is a pyrazole amide compound having fungicidal activity, with a structure shown by the general formula (I): | 2013-08-29 |
20130225586 | COMPOUNDS, COMPOSITIONS, PROCESSES OF MAKING, AND METHODS OF USE RELATED TO INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR - The present invention provides a compound having Formula I or II: | 2013-08-29 |
20130225587 | COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF - The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders. | 2013-08-29 |